The Hungarian National Focal Point just published its latest 2016 National Report on the recent developments of the drugs problem in Hungary. The National Report summarizes the developments in 2015 according to the international standards in eight workbooks. The Hungarian National Focal Point published the National Report about the latest trends in English and Hungarian languages in order to inform national and international experts, decision-makers and stakeholders, the wider public and the drugs agency of the European Union, the EMCDDA.
The 2015 National Report on the state of the drugs problem in Hungary (data on 2014) to the EMCDDA has been released by the Hungarian National Focal Point. The report provides a comprehensive overview on the latest trends of the drugs problem in Hungary in an updated format.
EMCDDA explores new dynamics and dimensions of Europe’s drugs problem
Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and ‘new drugs’ scene, are among the issues highlighted by the EU drugs agency (EMCDDA) today as it launches its European Drug Report 2015: Trends and Developments in Lisbon (1). In its annual review, the agency reflects on 20 years of monitoring and examines the global influences and local ramifications of Europe’s ever-changing drugs problem.
The EU drugs agency (EMCDDA) will be presenting its annual overview of the European drug situation on 27 May in a multilingual, multimedia information package focusing on today’s rapidly shifting drug phenomenon.
Central to the package is the European Drug Report 2014: Trends and Developments (in print and online in 23 languages), summarising the latest trends across the 28 EU Member States, Turkey and Norway. This top-level analysis explores: drug supply; drug use and drug-related problems; health and social responses to drug problems; and drug policies.
Accompanying the report will be Perspectives on Drugs (PODs), online interactive analyses providing insights into six topical issues (including cannabis markets in Europe and Internet-based drug treatment). The information package will be completed by a European Drug Data web area and Country Overviews offering national-level data and analyses. A tablet version, including interactive maps and graphics, will be available in English. Audiovisual material will also be on offer.